Medication for pediatric psychiatric disorders reduces later onset of substance use problems
Early and longer-lasting treatment reduces risk of substance use disorder most significantly.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Press Release5 Minute ReadApr | 22 | 2021
Krishna Reddy, MD, MSPeople who vape e-cigarettes in an effort to stop smoking tobacco cigarettes should be cautioned against using both and instead should switch over completely from smoking to vaping, with an ultimate goal of stopping vaping as well.
BOSTON – Exclusively using (or “vaping”) e-cigarettes can help people quit smoking, but many people using e-cigarettes to quit smoking continue to smoke cigarettes. New research led by investigators at Massachusetts General Hospital (MGH) reveals that respiratory symptoms—such as cough and wheeze—are more likely to develop when people use both e-cigarettes and tobacco cigarettes together compared with using either one alone. The findings are published in the American Journal of Respiratory and Critical Care Medicine, the flagship journal of the American Thoracic Society.
The investigators analyzed information on 20,882 individuals aged 12 years and older in the Population Assessment of Tobacco and Health (PATH) Study, a U.S. nationally representative longitudinal survey.
The analyzed participants had no respiratory symptoms when surveyed in 2015–2016. When they were surveyed about one year later, respiratory symptoms were reported by 10.7% of those who did not use e-cigarettes or tobacco cigarettes, 11.8% of exclusive e-cigarette users, 17.1% of exclusive tobacco smokers, and 19.7% of dual users (those who both vaped e-cigarettes and smoked tobacco cigarettes). Dual users had a 1.9-times higher odds of developing respiratory symptoms compared with exclusive e-cigarette users and a 1.24-times higher odds compared with exclusive tobacco smokers. The risk of new respiratory symptoms among individuals who vaped but did not smoke was not significantly higher than the risk among individuals who neither vaped nor smoked.
“To help people quit smoking, FDA-approved medications, such as the nicotine patch or the medication varenicline, are preferred,” says lead author Krishna Reddy, MD, MS, an investigator in MGH’s Division of Pulmonary and Critical Care Medicine and the MGH Tobacco Research and Treatment Center. “People who vape e-cigarettes in an effort to stop smoking tobacco cigarettes should be cautioned against using both and instead should switch over completely from smoking to vaping, with an ultimate goal of stopping vaping as well.”
Senior author Nancy Rigotti, MD, director of the Tobacco Research and Treatment Center, adds: “This study helps identify how e-cigarettes can best be used to reduce the harms caused by smoking cigarettes. Exclusive e-cigarette use did not increase the risk of new respiratory symptoms while using both products (e-cigarettes and cigarettes) did.”
Funding for the study was provided by the National Institute on Drug Abuse of the National Institutes of Health (NIH), the National Cancer Institute of the NIH and Food and Drug Administration Center for Tobacco Products, and the National Heart, Lung, and Blood Institute of the NIH.
Co-authors were Sara Kalkhoran, MD, MAS, and Eli Schwamm of MGH; Rochelle Walensky, MD, MPH, then of MGH, now of the Centers for Disease Control and Prevention; and Farzad Noubary, PhD, of Northeastern University.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
Early and longer-lasting treatment reduces risk of substance use disorder most significantly.
Preventing medication administration errors and improving efficiency during surgery enhances patient care.
ACTIVATE trial generated positive safety and efficacy data for mitapivat.
Important new clues about the genetic basis of schizophrenia have emerged in a landmark study led by investigators at the Analytic and Translational Genetics Unit (ATGU) at MGH and the Broad Institute of MIT and Harvard.
Women see gains in representation, but minority groups remain underrepresented.
Using reverse transcriptase inhibitors raises the possibility of a new therapeutic strategy in cancer.